Jun 28, 2023 8:00am EDT Sonnet BioTherapeutics Announces $2.25 Million Registered Direct Offering and Concurrent Private Placement
Jun 23, 2023 8:00am EDT Sonnet BioTherapeutics Announces Presentations at the 2023 Cytokine-Based Drug Development Summit and Provides Preliminary Update on the SON-080 Study in Chemotherapy-Induced Peripheral Neuropathy
Jun 20, 2023 8:00am EDT Sonnet BioTherapeutics Announces Regulatory Approval for Initiation of a Clinical Trial of SON-1010 Combined with Atezolizumab
May 10, 2023 7:30am EDT Sonnet BioTherapeutics Provides Fiscal Year 2023 Second Quarter and Year-to-Date Business and Earnings Update
Apr 18, 2023 4:01pm EDT Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 at the 2023 American Association for Cancer Research (AACR) Annual Meeting
Apr 17, 2023 8:00am EDT Sonnet BioTherapeutics Announces Webcast to Discuss Clinical Data from the SB101 Study with SON-1010 Being Presented at the AACR 2023 Annual Meeting
Mar 14, 2023 4:31pm EDT Sonnet BioTherapeutics to Present Clinical Data from the SB101 Study with SON-1010 at the AACR 2023 Annual Meeting
Feb 13, 2023 8:00am EST Sonnet BioTherapeutics Provides Fiscal Year 2023 First Quarter Business and Earnings Update
Feb 08, 2023 8:00am EST Sonnet BioTherapeutics Announces Pricing of $15.0 Million Underwritten Public Offering
Feb 01, 2023 8:00am EST Sonnet BioTherapeutics Announces Successful Completion of Two IND-Enabling Toxicology Studies with SON-1210 in Non-Human Primates
